Skip to main content
Caplight Logo









Novaremed AG

Novaremed AG

Private
BaselHealthcare & Life Scienceshttps://www.novaremed.com/

Last Round

PIPE

Jan 28, 2021

Company Overview

Novaremed AG is a biopharmaceutical company that develops small bio-molecule drugs for the treatment of neuropathic pain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalsmall molecule therapeuticschronic pain managementnon-opioid pain reliefdiabetic peripheral neuropathychemotherapy-induced peripheral neuropathypainkiller alternativesclinical-stage biotechdrug licensingneuropathic pain treatmentpain management pipelinenon-addictive pain medsdrug developmentbiotech R&Dclinical trials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Novaremed AG Comparables

Compare Novaremed AG with similar companies based on industry and business-model similarity.

Novaremed AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Plumeria Therapeutics, Inc.
85%
NeuroFront Therapeutics
84%
上海赛默罗生物科技有限公司
83%

Novaremed AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
PIPEJan 28, 2021
VC RoundSep 15, 2020
VC RoundSep 2, 2019
VC RoundAug 23, 2018
VC RoundApr 19, 2018

Key People

Founding team and executive leadership

Pasi Piitulainen

Chief Financial Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 28, 2021

    $50M raised from Gemny.

  • Sep 2, 2019

    Raised $2.63M in a VC Round.

Novaremed AG Filings

Explore SEC and related filing metadata, where available.

Novaremed AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Novaremed AG's valuation, stock price, and market status.

Is Novaremed a public or private company?

Novaremed is a private company.

What is the current stock price of Novaremed?

Novaremed is a private company with no public stock price. No recent secondary market data is available.

How much is Novaremed worth (valuation)?

Valuation information for Novaremed is not publicly available.

Can I buy Novaremed stock?

Novaremed shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Novaremed's last funding round?

Novaremed's most recent funding round was Private Placement on January 28, 2021.

Who are the main investors in Novaremed?

Investor information for Novaremed is not publicly disclosed.

Will Novaremed IPO soon?

No public IPO plans have been announced for Novaremed.

How can I track Novaremed secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Novaremed's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBasel
Employee Range5
Year Founded2008
Last FundingJan 28, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?